TearSolutions, Inc., a Charlotesville, VA-based biotech firm creating therapies for the remedy of ocular floor associated ailments, closed a $3M Collection B funding spherical.
The corporate intends to make use of the funds to speed up its growth packages for uncommon corneal ailments at each pre-clinical and scientific levels.
Led by Anil Asrani, President and CEO, TearSolutions is a biotechnology firm targeted on the invention, growth and commercialization of novel therapies for the remedy of sufferers with Ocular Floor Illness (OSD). The corporate is presently creating bioactive proprietary peptide proteoforms of lacritin.
Lacripep was patented by Dr. Gordon Laurie, a professor of Ophthalmology and Cell Biology on the College of Virginia, based mostly on his NIH funded analysis into the composition of human tears, which led to the invention of lacritin. Lacritin and Lacripep signify a singular remedy modality that optimizes all three layers of the tear movie whereas restoring corneal well being and homeostasis. The mental property is solely licensed to TearSolutions, Inc. from the College of Virginia Licensing and Ventures Group.
FinSMEs
21/11/2024
